CB-103   Click here for help

GtoPdb Ligand ID: 10517

Synonyms: CB103
Compound class: Synthetic organic
Comment: CB-103 is a first-in-class, small-molecule, orally active, pan-NOTCH inhibitor that is being investigated for anti-cancer potential [1-2]. It is being developed by Cellestia.
The CAS number provided within the full documentation for the study entitled 'A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study with Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult Patients with Advanced or Metastatic Solid Tumours and Haematological Malignancies Characterised by Alterations of the NOTCH Signalling Pathway' (EudraCT protocol 2017-001491-35) allowed us to identify a chemical structure for CB-103, frior to formal name>structure disclosure [2].
Information disclosed in meeting abstract form suggests that CB-103 acts by inhibiting protein-protein interactions that are required to establish assembly of the functional NOTCH transcription complex in the nucleus. By acting at the most downstream point in the NOTCH pathway, CB-103 inhibits NOTCH signalling independently of the mechanisms of NOTCH activation. NOTCH pathway signalling, and the approaches being explored for therapeutic targeting are reviewed by Sorrentino et al., 2019 [3].

CB-103 is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 48.14
Molecular weight 242.14
XLogP 3.98
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES Nc1ccc(nc1)Oc1ccc(cc1)C(C)(C)C
Isomeric SMILES Nc1ccc(nc1)Oc1ccc(cc1)C(C)(C)C
InChI InChI=1S/C15H18N2O/c1-15(2,3)11-4-7-13(8-5-11)18-14-9-6-12(16)10-17-14/h4-10H,16H2,1-3H3
InChI Key WHIWGRCYMQLLAO-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
CB-103 has advanced to Phase 1/2 clinical evaluation in patients with advanced/metastatic solid and hematological malignancies. Click here to link to ClinicalTrials.gov's full list of CB-103 studies.